At a glance
ClinicalIndex Comparison RecordEarly Ph 1Completed· 28 enrolled
Drug / intervention
Approved therapy will be assigned based on molecular profile and RPMA resultsdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study Utilizing Molecular Profiling by IHC, FISH, DNA Microarray, and Reverse Phase Protein Microarray (RPMA) of Patients' Tumors to Find Potential Targets and Select Treatments for Patients With Metastatic Breast Cancer.
In Brief
A Early Phase 1 clinical trial evaluating Approved therapy will be assigned based on molecular profile and RPMA results for Metastatic Breast Cancer. Completed, enrolled 28 participants across 3 sites.
Detailed Summary
The purpose of this study is to determine the response rate, that is the % of patients with non-progression of their metastatic breast cancer after 4 months on treatment that was selected by molecular testing and proteomics.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Breast Cancer
CountriesUnited States
CollaboratorsSide-Out Foundation
Timeline
Early Ph 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2010
Enrollment StartMar 2010
Primary CompletionJul 2012
TodayJul 2026
First PostedFeb 24, 2010
Enrollment StartMar 1, 2010
Primary CompletionJul 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 16.4 years ago
Interventions
Approved therapy will be assigned based on molecular profile and RPMA resultsdrug
treatment will be assigned based on IHC\< FISH, DNA microarray and RPMA results